Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Bicycle Therapeutics PLC as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 98
- −11 vs. Q4 2025
- Shares held
- 37.5M
- −1.71M (−4.4%) vs. Q4 2025
- Total value
- $173.6M
- −$103.3M (−37.3%) vs. Q4 2025
- New holders
- 15
- 43 more added
- Sold out
- 26
- 16 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0 | $0 | 0.00% | −568,225−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −297,247−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −146,100−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −111,659−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −96,401−100.0% | Sold out |
| Monimus Capital Management, LP | 0 | $0 | 0.00% | −93,840−100.0% | Sold out |
| Nan Fung Group Holdings Ltd | 0 | $0 | 0.00% | −68,943−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −46,728−100.0% | Sold out |
| Harbor Capital Advisors, Inc. | 0 | $0 | 0.00% | −40,486−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −21,548−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −19,986−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −19,771−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −14,138−100.0% | Sold out |
| JustInvest LLC | 0 | $0 | 0.00% | −12,776−100.0% | Sold out |
| Tocqueville Asset Management L.P. | 0 | $0 | 0.00% | −12,600−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −12,336−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −10,216−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −4,655−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −316−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −218−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −103−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −29−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |